Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
18 5월 2024 - 5:05AM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small molecule product candidates to address serious
diseases, including oncology and obesity, today announced that
members of senior management will be participating in a virtual
fireside chat at UBS Obesity Therapeutics Day on Thursday, May 23,
2024 at 1:00 p.m. ET.
A live webcast of the fireside chat will be available on the
investor relations page of the Terns Pharmaceuticals website
at http://ir.ternspharma.com. A replay of the webcast will be
archived on Terns’ website for 30 days following the event.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small molecule product candidates to
address serious diseases, including oncology and obesity. Terns’
pipeline includes three clinical-stage development programs
including an allosteric BCR-ABL inhibitor, a small molecule GLP-1
receptor agonist, a THR-β agonist, and a preclinical GIPR modulator
discovery effort, prioritizing a GIPR antagonist nomination
candidate. For more information, please
visit: www.ternspharma.com.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Terns Pharmaceuticals (NASDAQ:TERN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025